Страна: САЩ
Език: английски
Източник: NLM (National Library of Medicine)
ETHYNODIOL DIACETATE (UNII: 62H10A1236) (ETHYNODIOL - UNII:9E01C36A9S), ETHINYL ESTRADIOL (UNII: 423D2T571U) (ETHINYL ESTRADIOL - UNII:423D2T571U)
Physicians Total Care, Inc.
ETHYNODIOL DIACETATE
ETHYNODIOL DIACETATE 1 mg
PRESCRIPTION DRUG
Kelnor™ 28 Day Regimen) (ethynodiol diacetate and ethinyl estradiol tablets, USP) are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization and progestogen implants and injections, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. % of Women Experiencing an Unintended Pregnancy % of Women Continuing Use Method Typical Use† Perfect Use‡ Oral contraceptives should not be used in women who have the following conditions: - Thrombophlebitis or thromboembolic disorders - A past history of deep vein thrombophlebitis or thromboembolic disorders - Cerebral vascular disease, myocardial infarction, or coronary artery disease, or a past histor
Kelnor™ 1/35 (28 Day Regimen) (ethynodiol diacetate and ethinyl estradiol tablets, USP) are packaged in cartons of three blister card dispensers. Each blister card dispenser contains 21 light yellow, round, flat-faced, beveled-edge, unscored tablets, debossed with stylized b on one side and 14 on the other side and 7 white, round, flat-faced, beveled-edge, unscored placebo tablets, debossed with stylized b on one side and 143 on the other side. Each light yellow tablet contains 1 mg of ethynodiol diacetate and 0.035 mg of ethinyl estradiol. Each white tablet contains inert ingredients. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Keep this and all medications out of the reach of children.
Abbreviated New Drug Application
KELNOR 1/35 - ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL PHYSICIANS TOTAL CARE, INC. ---------- KELNOR™ 1/35 (28 DAY REGIMEN) (ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL TABLETS, USP) Revised MAY 2006 11001031 RX ONLY PATIENTS SHOULD BE COUNSELED THAT THIS PRODUCT DOES NOT PROTECT AGAINST HIV INFECTION (AIDS) AND OTHER SEXUALLY TRANSMITTED DISEASES. DESCRIPTION KELNOR™ 1/35 (28 DAY REGIMEN) (ethynodiol diacetate and ethinyl estradiol tablets, USP): Each light yellow tablet contains 1 mg of ethynodiol diacetate and 35 mcg of ethinyl estradiol. The inactive ingredients include anhydrous lactose, D&C yellow no. 10 aluminum lake, magnesium stearate, microcrystalline cellulose, polacrilin potassium, and povidone. Each white tablet is a placebo containing only inert ingredients as follows: anhydrous lactose, hypromellose, magnesium stearate, and microcrystalline cellulose. The chemical name for ethynodiol diacetate is 19-nor-17α-pregn-4-en-20-yne-3β, 17-diol diacetate, and for ethinyl estradiol it is 19-nor-17α-pregna-1, 3, 5 (10)-trien-20-yne-3, 17-diol. The structural formulas are as follows: ETHYNODIOL DIACETATE: C H O MOLECULAR WEIG HT: 384 .51 ETHINYL ESTRADIOL C H O MOLECULAR WEIG HT: 296.4 0 CLINICAL PHARMACOLOGY 24 32 4 20 24 2 Combination oral contraceptives act primarily by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations in the genital tract, including changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which may reduce the likelihood of implantation) may also contribute to contraceptive effectiveness. INDICATIONS AND USAGE KELNOR™ 28 DAY REGIMEN) (ethynodiol diacetate and ethinyl estradiol tablets, USP) are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and o Прочетете целия документ